ORKA · Oruka Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $29.14M | - | $28.99M | $24.09M | $19.93M | - | $25.69M | $130.0K | $165.0K | - |
| SG&A | $7.29M | - | $5.12M | $4.34M | $5.16M | - | $3.76M | $2.99M | $2.32M | - |
| Total Operating Expenses | $36.43M | - | $34.10M | $28.43M | $25.09M | - | $29.45M | $3.12M | $2.48M | - |
| D&A | $43.0K | - | - | - | $16.0K | - | - | - | $3.0K | - |
| Operating Income | ($36.43M) | - | ($34.10M) | ($28.43M) | ($25.09M) | - | ($29.45M) | ($3.12M) | ($2.48M) | - |
| Interest Expense | - | - | - | $750.0K | - | - | $504.0K | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | - | - | - |
| Net Income | ($31.82M) | - | ($30.28M) | ($24.57M) | ($21.00M) | - | ($28.62M) | ($2.68M) | ($1.09M) | - |
| EPS - Basic | - | - | - | ($0.46) | ($0.40) | - | ($1.46) | ($2.16) | ($1.68) | - |
| EPS - Diluted | - | - | - | ($0.46) | ($0.40) | - | ($1.46) | ($2.16) | ($1.68) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.52M | $46.94M | $91.25M | $65.40M | $83.57M | $61.58M | $410.88M | $33.28M | $35.90M | $37.43M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.66M | $4.16M | $2.21M | $4.66M | $3.54M | $3.46M | $2.15M | $571.0K | $529.0K | $362.0K |
| Current Assets | $395.25M | $343.86M | $355.16M | $332.01M | $352.08M | $376.87M | $412.95M | $33.82M | $36.67M | $37.59M |
| Total Assets | $504.48M | $488.62M | $509.25M | $357.42M | $377.11M | $396.02M | $414.09M | $33.84M | $36.71M | $37.86M |
| Current Liabilities | $16.63M | $15.37M | $20.97M | $12.11M | $11.72M | $13.04M | $18.04M | $1.27M | $1.58M | $637.0K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $17.76M | $16.69M | $22.46M | $13.78M | $12.39M | $13.80M | $18.88M | $1.27M | $1.58M | $841.0K |
| Stockholders' Equity | $486.72M | $471.93M | $486.79M | $343.64M | $364.73M | $382.22M | $1.0K | $32.57M | $35.13M | $37.02M |
| Retained Earnings | ($220.98M) | ($189.16M) | ($159.57M) | ($129.30M) | ($104.72M) | ($83.72M) | ($57.94M) | ($193.43M) | ($190.75M) | ($188.74M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.58M) | - | - | - | ($20.87M) | - | - | - | ($1.53M) | - |
| Investing Cash Flow | ($14.44M) | - | - | - | $42.87M | - | - | - | $0 | - |
| Financing Cash Flow | $40.60M | - | - | - | - | - | - | - | $0 | - |
| CapEx | $73.0K | - | - | - | $13.0K | - | - | - | - | - |
| Free Cash Flow | ($23.65M) | - | - | - | ($20.88M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.74 | - | - | - | 0.99 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.3% | - | -5.9% | -6.9% | -5.6% | - | -6.9% | -7.9% | -3.0% | - |
| Return on equity | -6.5% | - | -6.2% | -7.2% | -5.8% | - | -2862300.0% | -8.2% | -3.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 23.76 | 22.37 | 16.94 | 27.42 | 30.03 | 28.89 | 22.89 | 26.61 | 23.19 | 59.01 |
| Quick ratio | 23.76 | 22.37 | 16.94 | 27.42 | 30.03 | 28.89 | 22.89 | 26.61 | 23.19 | 59.01 |
| Cash ratio | 2.98 | 3.05 | 4.35 | 5.40 | 7.13 | 4.72 | 22.78 | 26.19 | 22.71 | 58.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -37.9x | - | - | -58.4x | - | - | - |
| Equity multiplier | 1.04 | 1.04 | 1.05 | 1.04 | 1.03 | 1.04 | 414090.00 | 1.04 | 1.05 | 1.02 |
| Liabilities / Assets | 0.04 | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | 0.05 | 0.04 | 0.04 | 0.02 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 1.4x | 1.2x | - | 367984.7x | 20.5x | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -45.2% | - | -15.8% | -810.6% | -910.7% | - | -1420.3% | - | -25.8% | - |
| Net income growth (YoY) | -51.5% | - | -5.8% | -817.6% | -1828.3% | - | -1910.0% | - | 7.2% | - |
| EPS growth (YoY) | - | - | - | 78.7% | 76.2% | - | -1360.0% | - | -1580.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -13.3% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 33.4% | 23.5% | 48679000.0% | 955.0% | 938.4% | 932.5% | -100.0% | - | -10.5% | -11.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Oruka Therapeutics against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months · -100.0% YoY
| Ex-date | Per share |
|---|---|
| Aug 29, 2024 | $19.3560 |